Arcturus Therapeutics Holdings Inc. — Form 8-K Summary
Business context and reporting period
Arcturus Therapeutics Holdings Inc., a Delaware biotechnology company listed on Nasdaq under the symbol ARCT, filed this Form 8-K regarding its annual meeting of stockholders held on June 18, 2021. The report was signed on June 22, 2021.
Financial metrics and liquidity
This filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, or other operating financial metrics.
Material changes and meeting results
- There were 26,320,275 shares entitled to vote, and 20,756,675 shares were present in person or by proxy, constituting a quorum.
- All seven director nominees were elected: Dr. Peter Farrell, Joseph E. Payne, Andy Sassine, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet, and Karah Parschauer.
- Votes in favor of the director nominees ranged from 13,860,947 to 17,096,507; broker non-votes were 3,403,915 for each nominee.
- Stockholders ratified Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021, with 20,726,502 votes for, 22,510 against, and 7,663 abstentions.
Guidance, outlook, risks, and unusual items
The filing provides no financial guidance, operational outlook, management commentary, new risk factors, contingencies, or unusual financial items. Its disclosures are limited to annual meeting voting results.
Key facts to verify
- Confirm the elected director slate and the directors’ subsequent committee assignments or changes in governance.
- Confirm Ernst & Young LLP’s appointment and any subsequent auditor changes.
- Review the Company’s periodic financial filings for current revenue, cash runway, operating losses, debt, liquidity, and development-program updates, none of which are provided in this Form 8-K.